SynthesisBMC cardiovascular disorders2025
Prognostic value of liver stiffness in patients with heart failure: a systematic review and meta-analysis.
Synthesis in BMC cardiovascular disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- CYP2D6 as an Emerging Endogenous Oxidative Stress Modulator in Cardiovascular Disease: Genetic, Pharmacological, and Redox Perspectives.Antioxidants (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsHeart failure (HF) is a complex, multisystemic condition affecting 64 million people worldwide and often leads to cardio-hepatic syndrome due to venous congestion and ischemic liver changes. Liver stiffness (LS) measured through elastographic methods has emerged as a potential noninvasive marker for cardiac outcomes in HF patients. However, its prognostic value and the implications for LS cutoff values remain uncertain, necessitating further investigation.
methodsMultiple databases (PubMed, Embase, Scopus and the Cochrane Library Database) were searched up to 1st September 2024. Two reviewers screened records and extracted data according to the inclusion and exclusion criteria. The methodological quality was evaluated using the National Heart, Lung and Blood Institute (NHLBI) for observational cohort and cross-sectional studies. The meta-analysis was performed using RevMan 5.4 and the meta-regression and publication bias analyses (including Egger's and Rank-correlation tests) were performed using JASP software, version 0.19.1.
resultsThirty-four studies involving 3753 individuals were included in our qualitative assessment, while 11 studies involving 1085 patients were included in the quantitative assessment. Elevated LS was significantly associated with adverse cardiac events in both acute decompensated HF (ADHF, hazard ratio (HR): 1.04, 95% CI: 1.01-1.07; I² = 61%) and chronic HF (CHF, HR: 1.09, 95% CI: 1.04-1.13; I² = 81%). Meta-regression revealed that LS cutoff values did not influence pooled estimates, and heterogeneity likely stemmed from demographic and methodological differences.
conclusionIncreased LS is associated with poor outcomes in patients hospitalized for HF, with a greater overall effect size in the CHF group than in the ADHF group. The LS is a promising noninvasive marker of liver congestion in HF and may aid both therapeutic decision-making and prognostication.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.